

Ref: FOI/GS/ID 6072

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

20 March 2020

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Ovarian Cancer.

*You asked:*

*Question 1*

*How many patients have been diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer?*

*If none, do you refer ovarian cancer patients to another trust, if so which one?*

*Question 2*

*Of the ovarian patients, how many have been tested for BRCA mutation?*

*If unknown please state unknown and move to Question 4*

*Question 3*

*Of the ovarian patient BRCA mutation tests how many tested positive?*

*Question 4*

*Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below:*

*Paclitaxel in combination with a platinum-based compound*

*Platinum-based therapy alone (cisplatin or carboplatin)*

*Bevacizumab in combination with paclitaxel and carboplatin*

*Olaparib*

*Niraparib*

*Rucaparib*

*Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound*

*Question 5*

*Of those who were positive for a BRCA mutation, how many received*

*Olaparib for 1st line maintenance?*

*Question 6*

*Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance?*

Trust response:

Question 1

Epithelial ovarian 31 (0),

Fallopian tube 1 (0)

Primary peritoneal cancer 0?

The Trust was not sure if epithelial related to all of the sub groups or just ovarian. To prevent confusion, the numbers above are the total number diagnosed and those in brackets are the number within that who have an epithelial histology code, i.e. 80823, 80933, 85623, 85883 or 89613. Data relates to diagnoses from 01/09/19 to 28/02/20.

Question 2

Unknown

Question 4

Paclitaxel in combination with a platinum-based compound 3

Platinum-based therapy alone (cisplatin or carboplatin) 3

Bevacizumab in combination with paclitaxel and carboplatin 2

Question 5

Not applicable

Question 6

Not applicable